Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460979 | 0.91 | ADORA3 (0.46) | KMT2APOLBMEN1VNN1USP2 | |
| SCHEMBL6478489 | 0.89 | LMNA (0.45) | KMT2APOLBMEN1VNN1USP2 | |
| SCHEMBL6479650 | 0.83 | MEN1 (0.54) | KMT2APOLBMEN1VNN1USP2 | |
| SCHEMBL5224357 | 0.82 | KMT2A (0.47) | KMT2APOLBMEN1USP2ALDH1A1 | |
| SCHEMBL5462040 | 0.82 | ADORA3 (0.42) | KMT2APOLBMEN1ALDH1A1LMNA | |
| SCHEMBL5964937 | 0.82 | ADORA3 (0.40) | KMT2AMEN1VNN1USP2ALDH1A1 | |
| SCHEMBL941232 | 0.82 | SMN1; SMN2 (0.42) | VNN1ALDH1A1LMNACYP3A4CYP2C9 | |
| SCHEMBL5224004 | 0.82 | ADORA3 (0.42) | KMT2APOLBMEN1ALDH1A1MAPK1 | |
| SCHEMBL6480798 | 0.81 | ALDH1A1 (0.48) | KMT2APOLBMEN1VNN1USP2 | |
| SCHEMBL940661 | 0.81 | MAPT (0.45) | KMT2AMEN1ALDH1A1MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390349-B1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20070249669-A1 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2007-10-25 | — | — | US | disclosed |
| EP-1740580-A2 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES , PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sanofi-Aventis (FR) | 2007-01-10 | — | — | EP | disclosed |
| US-6969723-B2 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI - AVENTIS (FR) | 2005-11-29 | — | — | US | disclosed |
| WO-2005100320-A2 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI (FR) | 2004-09-23 | — | — | US | disclosed |
| EP-1390349-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002096879-A9 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SYNTHELABO (FR) | 2003-11-20 | — | — | WO | disclosed |
| WO-2002096879-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249669-A1 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SFPQ, ADRB3, KCNQ3 | KMT2A 2114/4885POLB 3480/4885MEN1 907/4885 |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | ADORA3, ADORA1, ADORA2A | KMT2A 2739/4885POLB 2011/4885MEN1 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.